Vicore Pharma Holding ABVCRE -4.00%13 EV-to-EBIT is -89.74 as of Jul. 07, 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 365 Biotechnology companies, Vicore Pharma Holding AB ranks worse than 273972.33% on this metric.
Vicore Pharma Holding AB (NAS:VCRE) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vicore Pharma Holding AB's Enterprise Value for the quarter that ended in Mar. 2026 was $0.00 Mil.
Vicore Pharma Holding AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB EV-to-EBIT Related Terms
Vicore Pharma Holding AB EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vicore Pharma Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's EV-to-EBIT falls into.
Vicore Pharma Holding AB's current Enterprise Value is $4,281.89 Mil.
Vicore Pharma Holding AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB (VCRE) has a EV-to-EBIT of -89.74 as of Jul. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vicore Pharma Holding AB and its competitors. According to the industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 365 companies in the Biotechnology industry.
Is Vicore Pharma Holding AB's EV-to-EBIT too high?
Vicore Pharma Holding AB's current EV-to-EBIT is -89.74. Based on the distribution chart, Vicore Pharma Holding AB ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's EV-to-EBIT compare to ?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 365 companies for EV-to-EBIT. This places Vicore Pharma Holding AB in the lower half of its industry. The industry median EV-to-EBIT is 14.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.69, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vicore Pharma Holding AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicore Pharma Holding AB's current EV-to-EBIT is -89.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current EV-to-EBIT of -89.74. The current EV-to-EBIT is -89.74. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current EV-to-EBIT is -89.74 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score
Get the complete analysis for VCRE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCRE has been successfully added to your 
